• Defence Therapeutics Inc. (DTC) has given an update on its antibody-drug conjugate (ADC) programs undergoing development using its candidate drug, Accum
  • Defence and the Curie Institute are working on an efficacy study of the drug in a patient-derived model for breast cancer
  • Collaboration with the HUS Comprehensive Cancer Center has been extended to test Accum against other treatments for fighting cancer in tumors
  • The Institut de Recherche en Cancérologie de Montpellier (IRCM) and Defence are working on two in vivo studies in hopes they can increase the drug treatment ratio
  • Defence Therapeutics Inc. (DTC) is unchanged trading at $2.00 per share as of 9:41 a.m. ET

Defence Therapeutics (DTC) has provided an update on its antibody-drug conjugate (ADC) programs undergoing development using its candidate drug, Accum.

According to Defence, the Curie Institute, one of the collaborators, is performing an efficacy study of Accum-T-DM1 (antibody) ADC in a patient-derived model for breast cancer.

After which, a comparison study will analyze the safety of T-DM1 against Accum T-DM1 in mice. Defence is expecting to see the study’s results sometime between its third and fourth quarter.

T-DM1, under the brand Kadcyla, is used to treat women with metastatic HER2-positive breast cancer. Defence stated this study is meant to prove that the current treatment may be improved using the Accum technology through the drug’s delivery to the tumour cells.

Defence commented it is extending its collaboration with the HUS Comprehensive Cancer Center. The collaboration includes comparisons of T-DM1 versus Accum-T-DM1 versus co-treatment of AccuTOX variants by injecting it within a tumour. Results from these studies are expected sometime at the end of this year.

The Institut de Recherche en Cancérologie de Montpellier (IRCM), is executing in vivo studies using AccumTM with radio-immuno-therapeutic combinations. Defence hopes to strengthen the ratio of the drug while minimizing side effects. Results are expected to be released in the second half of this year.

Defence stated it is also working with WASSC Technologies to develop a new small molecule for ADC application. Toxicity results of variants are expected to arrive during the third quarter.

Defence Therapeutics Inc. (DTC) is unchanged trading at $2.00 per share as of 9:41 a.m. ET.

More From The Market Online

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.
WELL Health - Hamed Shahbazi, Founder and CEO (third from right).

WELL Health streamlining business towards profitable growth

WELL Health (TSX:WELL) has made an integration update to streamline its business operations and position itself for profitable growth.

An investor’s gateway into the cancer immunotherapy market is with this Canadian biotechnology company 

The overarching cancer immunotherapy market continues growing at unprecedented rates, and BioVaxys Technology is ready to capitalize on it.

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.